PBM
TRVI icon

Propel Bio Management’s Trevi Therapeutics TRVI Stock Holding History

Propel Bio Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-223,802
Closed -$2.65M – 36
2026
Q1 		$2.65M Buy
+223,802
New +$2.51M 1.67% 22
2024
Q3 		– Sell
-260,000
Closed -$775K – 25
2024
Q2 		$775K Hold
260,000
– – 0.5% 20
2024
Q1 		$897K Buy
+260,000
New +$580K 0.52% 22

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Propel Bio Management's TRVI Position: Q2 2026 in Review

Propel Bio Management sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 223,802 shares — an estimated $2.65M sold.

Propel Bio Management first reported a position in TRVI in Q1 2024 and held it in 3 quarters. The position peaked at $2.65M in Q1 2026. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Propel Bio Management reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Propel Bio Management sold 223,802 Trevi Therapeutics shares in Q2 2026, an estimated $2.65M.
  • Propel Bio Management first reported a position in Trevi Therapeutics in Q1 2024 and held it in 3 quarters.
  • Propel Bio Management's Trevi Therapeutics position peaked at $2.65M in Q1 2026.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.